Iambic Therapeutics’ Post

How Biotechs Are Plugging AI into Drug Discovery Problems P.S. If you like this post please 1) Like it (so I know it's useful) and 2) Repost and share it (so others can see it too)

Boehringer Deploys IBM's GenAI Into its Antibody Discovery Efforts In another example of the pharma industry embracing generative artificial intelligence (genAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibody discovery and development. The partnership announced this week will see the German pharma group deploy IBM’s foundation model technologies – machine learning models that can be trained on unlabeled data to carry out a range of applications – in its R&D operations. According to the two companies, Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data with the aim of coming up with “efficient therapeutics.” https://lnkd.in/g7Jj9-Rm #aspenalert #biotech #bioprocess

How Biotechs Are Plugging AI into Drug Discovery Problems P.S. If you like this post please 1) Like it (so I know it's useful) and 2) Repost and share it (so others can see it too)

We have launched a tech scout and competitive intelligence report, "The State of AI in the Biopharma Industry," and the video overview has arrived 👇 📽 A 150-page PDF report includes: - Comprehensive overview of AI in Life Sciences - Key AI concepts, trends - 500+ AI-driven companies, dozens of tech case studies - AI across the drug R&D landscape - AI across therapeutic modalities: from small molecules and proximity-inducing modalities to biologics and therapies - AI in synthetic biology and biomanufacturing - Mapping opportunities and risks - AI-centered business models, strategy insights You also get access to an interactive dashboard to navigate through the data about 500+ companies. Make sure to access "The State of AI in the Biopharma Industry" early; prices will be going up as we add more companies and case studies! #biopharmatrend #businessintelligence #marketanalysis #competitiveintelligence #drugdiscovery #artificialintelligence

We have launched a tech scout and competitive intelligence report, "The State of AI in the Biopharma Industry," and the video overview has arrived 👇 📽 A 150-page PDF report includes: - Comprehensive overview of AI in Life Sciences - Key AI concepts, trends - 500+ AI-driven companies, dozens of tech case studies - AI across the drug R&D landscape - AI across therapeutic modalities: from small molecules and proximity-inducing modalities to biologics and therapies - AI in synthetic biology and biomanufacturing - Mapping opportunities and risks - AI-centered business models, strategy insights You also get access to an interactive dashboard to navigate through the data about 500+ companies. Make sure to access "The State of AI in the Biopharma Industry" early; prices will be going up as we add more companies and case studies! #biopharmatrend #businessintelligence #marketanalysis #competitiveintelligence #drugdiscovery #artificialintelligence

Recursion, a leading biotech company pioneering data-driven drug discovery, just unveiled "LOWE" - A generative AI platform. Imagine a powerful AI assistant for scientists, trained to navigate Recursion's vast library of machine learning models. With LOWE, researchers can: Combine insights from multiple models simultaneously, saving precious time and effort. Design and test new drug candidates, without writing a single line of code, uncover hidden connections and patterns in complex biological data, leading to faster breakthroughs. Impact? 💡 It drastically shorten the time it takes to bring new drugs to market, reduce the cost of research and development and increase the success rate of identifying promising drug candidates. This is a game-changer for patients waiting for life-saving treatments, pharmaceutical companies seeking to develop innovative drugs the entire healthcare industry striving for improved outcomes #ai #healthcare #innovation

📢 Sanofi, OpenAI, and Formation Bio Collaborate for AI-Driven Drug Development Three companies have united to accelerate drug development through cutting-edge AI technology. 🔬 What does the partnership mean? 🔹Sanofi will provide access to proprietary data to develop advanced AI models for biopharma. 🔹OpenAI responsible for AI capabilities, fine-tuning models, and deep AI expertise. 🔹Formation Bio will supply engineering resources and a tech-driven development platform. 💡 Main goals: This collaboration aims to create custom solutions, set new industry standards, and significantly benefit patients awaiting new treatments. With an understanding of rapid technology growth, Data Science UA offers flexible AI solutions in drug discovery, adaptable to industry trends. #healthcare #pharma #techevolution #collaboration #innovation #ai #openai #datascienceua

An in-depth perspective on the CACHE Competition and the outcomes of CACHE Challenge 1 is now published in Nature Reviews Drug Discovery. Learn how CACHE is revolutionizing AI-assisted drug discovery, with insightful quotes from experts in the field, who emphasize the need for transparency and collaboration in improving hit-finding methods. Read the full article here: https://lnkd.in/gKP77iqf #AI #DrugDiscovery #CACHEChallenge #NatureReviews #ScienceNews

AI's Breakthrough in Drug Discovery Discover how AI is revolutionizing drug discovery, making it faster and more precise. Our new bar chart, based on insights from Boston Consulting Group and Wellcome, visually demonstrates the significant reduction in time and cost for AI-assisted methods compared to traditional ones. hashtag #AIinHealthcare hashtag #DrugDiscovery hashtag #PersonalizedMedicine hashtag #BostonConsultingGroup hashtag #Wellcome Explore AI's role in transforming drug discovery. Read more in our special edition newsletter!' Read More https://lnkd.in/eau6sC6a

CACHE competition: Unveiling the power and limitations of AI in drug discovery The results are in from the CACHE hit-finding competition, and they offer a fascinating glimpse into the potential of AI for drug discovery. Over 2,000 compounds, 23 teams, and a tough Parkinson's target yielded a <1% hit rate. But hey, that's not a failure – this transparency around data and methods is a crucial step forward, as it paves the way for independent validation and fuels collaboration. This is exactly what we need to refine computational/AI driven driven hit-finding and unlock its true potential. What are your thoughts on the CACHE results? Hit reply and share your insights! #drugdiscovery #ai #CACHECompetition #aidrugdiscovery